Candesartan CAS 139481-59-7 Purity >99.0% (HPLC) Factory

Short Description:

Chemical Name: Candesartan

CAS: 139481-59-7

Purity: >99.0% (HPLC)

Appearance: White Powder

A Selective Angiotensin II Receptor Antagonist

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Ruifu Chemical Supply Candesartan Cilexetil Intermediate With High Purity
Candesartan Cilexetil CAS 145040-37-5
Candesartan CAS 139481-59-7
1-Chloroethyl Cyclohexyl Carbonate CAS 99464-83-2
Candesartan Cilexetil Intermediate Eethyl Ester C6 CAS 139481-41-7
Candesartan Cilexetil Intermediate CAS 139481-44-0
Trityl Candesartan Cilexetil CAS 170791-09-0

Chemical Properties:

Chemical Name	Candesartan
Synonyms	CV-11974; 2-Ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-Benzimidazole-7-Carboxylic Acid; 3-[[2'-(1H-Tetrazol-5-yl)biphenyl-4-yl]methyl]-2-ethoxy-3H-Benzimidazole-4-Carboxylic Acid; Candesartan M1; Candesartan Cilexetil EP Impurity G
CAS Number	139481-59-7
CAT Number	RF-PI1889
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C24H20N6O3
Molecular Weight	440.45
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White Powder
Identification-HPLC	The Retention Time Similar to Standard
Identification-IR	Similar to Standard
Purity / Analysis Method	>99.0% (HPLC)
Melting Point	183.0~185.0℃
Loss on Drying	<0.50%
Moisture (K.F)	<0.50%
Residue on Ignition	<0.50%
Heavy Metals	<20ppm
Individual Impurity	<1.00% (HPLC)
Total Impurities	<1.00% (HPLC)
Refractive Index	n20/D 1.745~1.747
Test Standard	Enterprise Standard
Usage	API; For the Treatment of Hypertension

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

Application:

Candesartan (CAS: 139481-59-7) is an angiotensin II receptor antagonist with IC50 of 0.26 nM. Target: Angiotensin II Receptor candesartan is indicated for the treatment of hypertension. Candesartan Cilexetil was first approved in GB on Apr 29, 1997, then approved by the U.S. Food and Drug Administration (FDA) on June 4, 1998, and approved by Pharmaceuticals and Medical Devices Agency of Japan (PMDA) on Mar 12, 1999. It was developed by AstraZeneca, then marketed as Atacand by AstraZeneca in GB and the US, and marketed as Blopress by Takeda in JP. Candesartan Cilexetil is an angiotensin II receptor blocker (ARB), it blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Atacand is indicated for the treatment of hypertension in adults and children 1 to < 17 years of age, heart failure (NYHA class II-IV) and used to reduce cardiovascular death and heart failure hospitalization.